Business
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended March 31, 2025. “The third quarter of 2025 represents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development program,” said Joel
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended March 31, 2025.","length":347,"tagName":"p"},{"type":"text","content":"“The third quarter of 2025 represents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development program,” said Joel Latham, President and CEO of Incannex. “With the rapid completion of Phase 2 enrollment in the Phase 2/3 RePOSA, recent positive and confirmatory PK and safety clinical results, and the addition of expert sleep medicine clinical advisory leadership, we are well-positioned to deliver on key upcoming milestones and to advance IHL-42X as a potential treatment for millions of underserved patients living with OSA.”","length":566,"tagName":"p"},{"type":"text","content":"Operational Highlights","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Secured $12.5 million USD in private placement funding, priced at-the-market under Nasdaq rules. Proceeds will support the ongoing IHL-42X Phase 2/3 obstructive sleep apnea (OSA) clinical program, including completion of the Phase 2 study, topline data readout, and expansion into Phase 3.","length":289,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced the formation of an OSA Clinical Advisory Board and the appointment of Alison Wimms, Ph.D., representing ResMed. Dr. Wimms brings over 20 years of sleep medicine industry and research expertise. The establishment of this new advisory board marks an important step in advancing collaboration and the late-stage clinical development of IHL-42X f...